<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179552</url>
  </required_header>
  <id_info>
    <org_study_id>CON-OA</org_study_id>
    <nct_id>NCT04179552</nct_id>
  </id_info>
  <brief_title>PAAG-OA Treatment for Knee Osteoarthritis</brief_title>
  <acronym>IDA</acronym>
  <official_title>Prospective, Open-label Clinical Investigation of Intra-articular Polyacrylamide Hydrogel Injection in Subjects With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contura</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Contura</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, prospective, open-label, uncontrolled, clinical investigation
      followed by an open-label extension clinical investigation to evaluate PAAG-OA in patients
      with knee osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 21, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the WOMAC pain subscale</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate the effectiveness of one injection of PAAG-OA on pain over 3 months in subjects with mild to severe knee OA. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMAC</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>To evaluate the effectiveness of one injection of PAAG-OA on knee OA-related subject reported symptoms, function during activities of daily living. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PGA</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>To evaluate the effectiveness of one injection of PAAG-OA on knee OA Patient Global Assessment (PGA). PGA is reported on a 10 cm Visual Analogue Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>To evaluate the extended effectiveness of 6 ml PAAG-OA on knee OA-related subject reported symptoms, function during activities of daily living over 6 and 12 months. Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale where a score of 0=none, and 4=extreme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGA</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>To evaluate the extended effectiveness of 6 ml PAAG-OA on knee OA-related Patient Global Assessment (PGA) over 6 and 12 months. PGA is reported on a 10 cm Visual Analogue Scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>PAAG-OA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects receive treatment with PAAG-OA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAAG-OA</intervention_name>
    <description>Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)</description>
    <arm_group_label>PAAG-OA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Male or female, aged ≥ 18 years

          4. Clinical diagnosis of knee OA according to American College of Rheumatology criteria

          5. Definite radiographic OA in target knee at mild to severe stage (Kellgren-Lawrence
             2-4)

          6. Stable dose of analgesics for the past four weeks

          7. Score of 2 or more (0-4 scale) on WOMAC question A1 (pain while walking on flat
             surface)

          8. Body Mass Index (BMI) &lt;35

          9. For females of reproductive potential: use of adequate contraception must be used
             throughout the trial

        Exclusion Criteria:

          1. Female participants who are pregnant, lactating or planning pregnancy during the
             course of the clinical investigation

          2. Previous intra-articular injection of polyacrylamide gel in the target knee

          3. Previous intra-articular injection with hyaluronic acid or derivatives in target knee
             in the previous 6 months

          4. Significant valgus/varus deformity of the knee, ligamentous laxity or meniscal
             instability

          5. Diseases in target knee other than OA

          6. Intra-articular injection of any substance other than hyaluronic acid (e.g.
             corticosteroids) in the target knee within the last 3 months

          7. Acute serious infection of any region that required hospital care or intravenous
             antibiotic treatment within the last 30 days, or oral antibiotic treatment within the
             last 14 days

          8. Skin disease or infections in the area of the injection site

          9. History of sepsis in any joint or any clinical concern for an infectious process in
             the target knee

         10. History of surgery in the target knee within the past 6 months

         11. Symptomatic osteoarthritis of the hips, spine or ankle, that interferes with the
             evaluation of the target knee

         12. Planned surgery on any lower extremity

         13. Clinically significant venous of lymphatic stasis present in the legs

         14. Suffering from any unstable or severe cardio-vascular disease

         15. Any other contraindication to intra-articular injection

         16. Any foreign material in the target joint

         17. Any significant medical condition (e.g. significant psychiatric or neurological
             disorders or active alcohol/drug abuse) that is unstable/poorly controlled or other
             factors that may interfere with study participation

         18. Treatment with systemic steroids with daily doses equivalent of &gt;7,5 mg prednisolone

         19. Significant change in physiotherapy in lower extremities related to OA within the
             previous month

         20. Fibromyalgia

         21. Inflammatory or other disease/condition which may affect the knee joint (e.g.
             rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis among others)

         22. Haemophilia

         23. Any other condition that in the opinion of the investigator puts a potential
             participant at risk or otherwise precludes participation in the investigation

         24. Known allergic reactions to antibiotics (azithromycin and moxifloxacin) or local
             anaesthesia

         25. Participation in any experimental device study within 6 months prior to enrolment, or
             participation in an experimental drug study within 1 month prior to enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bliddal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Parker Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Parker Institute</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A2 Reumatologi og Idrætsmedicin</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatolog i Odense</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

